<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336170">
  <stage>Registered</stage>
  <submitdate>29/10/2010</submitdate>
  <approvaldate>5/11/2010</approvaldate>
  <actrnumber>ACTRN12610000952044</actrnumber>
  <trial_identification>
    <studytitle>The Role of male sex hormone in Angiogenesis and Endothelial Progenitor Cell Mobilisation</studytitle>
    <scientifictitle>The Role of Androgens in Angiogenesis and Endothelial Progenitor Cell Mobilisation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>n/a</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>effect of androgen on formation of new blood vessels</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Normal development and function of the cardiovascular system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Normal metabolism and endocrine development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Primoteston (testosterone enanthate) 250mg intramuscular injection weekly for 6 weeks</interventions>
    <comparator>placebo is normal saline</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>endothelial progenitor cell functions assessment after treatment using in vitro assay (Asahara stain, Boyden chamber, and tubulogenesis assay), and in vivo model (cells transplanted to mice)</outcome>
      <timepoint>6 weeks after randomization (on completion of treatment)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>effect on flow-mediated dilatation (FMD) of brachial artery using ultrasound</outcome>
      <timepoint>6 weeks after randomization (on completion of treatment)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>all males, except for those aged 35-55 years old, and 18 is the minimum age</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>diabetes, prostate problem, on statin treatment, significant medical illness</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>15/01/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Heart Research Institute</primarysponsorname>
    <primarysponsoraddress>7 Eliza St, Newtown, NSW, 2042</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National and Health Medical Research Council</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Martin Ng</sponsorname>
      <sponsoraddress>Cardiology Department, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to assess the effects of testosterone on endothelial progenitor cells numbers and function in men. By understanding the effects of testosterone on endothelial progenitor cells, we may be able to better understand the potential role that male sex hormones may play in maintaining heart and blood vessel function in men. This research may ultimately lead to new treatments to help with heart and blood vessel repair.

To Public:
This study aims to assess the effect of male sex hormone on the male stem cells. By understanding the effect we may be able to use male sex hormone to maintain human heart and blood vessel function in men.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Review Committee (RPAH Zone) of the Sydney South West Area Health Service</ethicname>
      <ethicaddress>Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050</ethicaddress>
      <ethicapprovaldate>30/08/2007</ethicapprovaldate>
      <hrec>X07-0159</hrec>
      <ethicsubmitdate>1/06/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Chi-Jen Hsu</name>
      <address>7 Eliza St, Newtown, NSW, 2042</address>
      <phone>+61-2-82088900</phone>
      <fax />
      <email>cjhsu888@gmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Chi-Jen Hsu</name>
      <address>7 Eliza St, Newtown, NSW, 2042</address>
      <phone>+61-2-82088900</phone>
      <fax />
      <email>cjhsu888@gmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Chi-Jen Hsu</name>
      <address>as above</address>
      <phone>+61-2-82088900</phone>
      <fax />
      <email>cjhsu888@gmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>